Cargando…

Dynamic (11)C-Choline PET / CT for the primary diagnosis of prostate cancer

OBJECTIVES: To test the ability of dynamic (11)C-PET / CT to discriminate cancerous tissue from background tissue in patients with localized prostate cancer. MATERIALS AND METHODS: Twenty-four consecutive patients with prostate cancer were prospectively evaluated with dynamic (11)C-choline PET / CT...

Descripción completa

Detalles Bibliográficos
Autores principales: Golan, Shay, Nidam, Meital, Bernstine, Hanna, Baniel, Jack, Groshar, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Urologia 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237539/
https://www.ncbi.nlm.nih.gov/pubmed/30088719
http://dx.doi.org/10.1590/S1677-5538.IBJU.2018.0035
_version_ 1783371202227601408
author Golan, Shay
Nidam, Meital
Bernstine, Hanna
Baniel, Jack
Groshar, David
author_facet Golan, Shay
Nidam, Meital
Bernstine, Hanna
Baniel, Jack
Groshar, David
author_sort Golan, Shay
collection PubMed
description OBJECTIVES: To test the ability of dynamic (11)C-PET / CT to discriminate cancerous tissue from background tissue in patients with localized prostate cancer. MATERIALS AND METHODS: Twenty-four consecutive patients with prostate cancer were prospectively evaluated with dynamic (11)C-choline PET / CT prior to radical prostatectomy. The PET / CT scan was divided into 18 sequences of 5 seconds each, followed by 9 sequences of 60 seconds each. Whole-mount sections of harvested prostates served as reference standards. Volumes of interest were positioned on the dynamic PET / CT images and the following quantitative variables were calculated: perfusion coefficient (K1), washout constant (K2), area under the curve (AUC) at 175 and 630 seconds, and average and maximum standardized uptake values (SUV(avg), and SUV(max)). Wilcoxon signed-ranks test was used to compare benign and cancerous areas of the prostate. RESULTS: Areas of cancerous tissue were characterized by higher SUV(avg) and SUV(max) than areas of benign tissue (3.67 ± 2.7 vs. 2.08 ± 1.3 and 5.91 ± 4.4 vs. 3.71 ± 3.7, respectively, P < 0.001), in addition to a higher K1 (0.95 ± 0.58 vs. 0.43 ± 0.24, P < 0.001) and greater cumulative tracer uptake, represented by the AUC at 175 and 630 seconds (P <0.001). No associations were found between dynamic parameters and preoperative prostate specific antigen level or Gleason score. CONCLUSIONS: In this pilot study, (11)C-choline PET / CT demonstrated increased tracer uptake with higher values of static and dynamic parameters in areas of prostate cancer compared to areas of benign tissue. Larger studies are warranted to validate these results and examine the potential applicability of (11)C-choline dynamic PET / CT for the diagnosis of prostate cancer.
format Online
Article
Text
id pubmed-6237539
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Sociedade Brasileira de Urologia
record_format MEDLINE/PubMed
spelling pubmed-62375392018-11-19 Dynamic (11)C-Choline PET / CT for the primary diagnosis of prostate cancer Golan, Shay Nidam, Meital Bernstine, Hanna Baniel, Jack Groshar, David Int Braz J Urol Original Article OBJECTIVES: To test the ability of dynamic (11)C-PET / CT to discriminate cancerous tissue from background tissue in patients with localized prostate cancer. MATERIALS AND METHODS: Twenty-four consecutive patients with prostate cancer were prospectively evaluated with dynamic (11)C-choline PET / CT prior to radical prostatectomy. The PET / CT scan was divided into 18 sequences of 5 seconds each, followed by 9 sequences of 60 seconds each. Whole-mount sections of harvested prostates served as reference standards. Volumes of interest were positioned on the dynamic PET / CT images and the following quantitative variables were calculated: perfusion coefficient (K1), washout constant (K2), area under the curve (AUC) at 175 and 630 seconds, and average and maximum standardized uptake values (SUV(avg), and SUV(max)). Wilcoxon signed-ranks test was used to compare benign and cancerous areas of the prostate. RESULTS: Areas of cancerous tissue were characterized by higher SUV(avg) and SUV(max) than areas of benign tissue (3.67 ± 2.7 vs. 2.08 ± 1.3 and 5.91 ± 4.4 vs. 3.71 ± 3.7, respectively, P < 0.001), in addition to a higher K1 (0.95 ± 0.58 vs. 0.43 ± 0.24, P < 0.001) and greater cumulative tracer uptake, represented by the AUC at 175 and 630 seconds (P <0.001). No associations were found between dynamic parameters and preoperative prostate specific antigen level or Gleason score. CONCLUSIONS: In this pilot study, (11)C-choline PET / CT demonstrated increased tracer uptake with higher values of static and dynamic parameters in areas of prostate cancer compared to areas of benign tissue. Larger studies are warranted to validate these results and examine the potential applicability of (11)C-choline dynamic PET / CT for the diagnosis of prostate cancer. Sociedade Brasileira de Urologia 2018 /pmc/articles/PMC6237539/ /pubmed/30088719 http://dx.doi.org/10.1590/S1677-5538.IBJU.2018.0035 Text en https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Golan, Shay
Nidam, Meital
Bernstine, Hanna
Baniel, Jack
Groshar, David
Dynamic (11)C-Choline PET / CT for the primary diagnosis of prostate cancer
title Dynamic (11)C-Choline PET / CT for the primary diagnosis of prostate cancer
title_full Dynamic (11)C-Choline PET / CT for the primary diagnosis of prostate cancer
title_fullStr Dynamic (11)C-Choline PET / CT for the primary diagnosis of prostate cancer
title_full_unstemmed Dynamic (11)C-Choline PET / CT for the primary diagnosis of prostate cancer
title_short Dynamic (11)C-Choline PET / CT for the primary diagnosis of prostate cancer
title_sort dynamic (11)c-choline pet / ct for the primary diagnosis of prostate cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237539/
https://www.ncbi.nlm.nih.gov/pubmed/30088719
http://dx.doi.org/10.1590/S1677-5538.IBJU.2018.0035
work_keys_str_mv AT golanshay dynamic11ccholinepetctfortheprimarydiagnosisofprostatecancer
AT nidammeital dynamic11ccholinepetctfortheprimarydiagnosisofprostatecancer
AT bernstinehanna dynamic11ccholinepetctfortheprimarydiagnosisofprostatecancer
AT banieljack dynamic11ccholinepetctfortheprimarydiagnosisofprostatecancer
AT groshardavid dynamic11ccholinepetctfortheprimarydiagnosisofprostatecancer